Synchronized drug-device neuroplasticity

Synchronized drug-device neuroplasticity, clinically referred to as combination therapy with TMS and ketamine (CTK), is an interventional psychiatric protocol that synchronizes the administration of transcranial magnetic stimulation (TMS) with a dissociative NMDA receptor antagonist (typically racemic ketamine or esketamine). The protocol is primarily studied as an alternative treatment standard for major depressive disorder (MDD) and severe treatment-resistant depression (TRD). It has also been evaluated for comorbid neuropsychiatric conditions, including generalized anxiety disorder (GAD), substance use disorders (SUD), and neuropathic pain.

The underlying therapeutic thesis posits that combining molecular psychopharmacology with precise focal neuromodulation achieves structural and functional neuroplastic changes that surpass the physiological boundaries of standalone monotherapies.

Neurobiological mechanisms

While standalone repetitive TMS or ketamine infusions demonstrate baseline efficacy, both modalities possess documented boundaries: high-intensity motor-threshold TMS parameter protocols routinely encounter barriers with scalp intolerability , whereas subanesthetic ketamine infusions frequently suffer from brief therapeutic windows and low long-term durability. The protocol's hypothesized synergistic actions span several functional levels:

Molecular and synaptic level

Ketamine acts primarily as a non-competitive antagonist of N-methyl-D-aspartate receptors (NMDAR) on GABAergic interneurons. This causes a downstream glutamatergic surge that activates postsynaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Simultaneously, TMS generates focal electric currents that induce neurogenesis and activate long-term potentiation (LTP) pathways. Together, both interventions are hypothesized to mutually reinforce the upregulation of brain-derived neurotrophic factor (BDNF) and mammalian target of rapamycin (mTOR) signaling pathways. This cellular cascade accelerates synaptogenesis, synaptic modulation, and dendritic arborization growth.

Cortical excitability and pain pathways

Independent pharmaco-TMS-EEG paradigms mapping the dorsolateral prefrontal cortex (DLPFC) show that a subanesthetic dose (0.5" mg/kg" ) of ketamine decreases prefrontal cortical excitability measures (indexed via local mean field amplitude-area under the curve, or LMFA-AUC) within 4 hours, which normalizes over 24 hours. Additionally, animal models demonstrate that ketamine reliably induces synchronized cortical activities, known as Poly Population Spikes (PPS). These PPS can be effectively and reversibly suppressed by subthreshold repetitive TMS, indicating a convergent but opposing modulation on cortical circuits. Clinically, the systemic analgesic effect of ketamine temporarily alters the brain's state during stimulation. This allows patients to tolerate low-frequency, high-intensity TMS (e.g., at or above 130% of the resting motor threshold) to central targets like the anterior cingulate cortex (ACC) without provoking severe localized scalp discomfort.

Network level

Depressive disorders are characterized by aberrant resting-state functional connectivity, particularly overactivity within the default mode network (DMN) and uncoupled communication with the salience network (SN). In combination protocols, ketamine provides rapid initial chemical disinhibition and neuroplasticity across prefrontal and limbic regions. This sets a responsive substrate for TMS (TMS, rTMS, theta-burst stimulation/TBS) to effectively recalibrate global network configurations, dampening DMN hyperconnectivity and reducing clinical symptoms of ruminative thought.

Clinical evidence and systematic review

Template:AI-generated section A comprehensive systematic review analyzed clinical studies on the concurrent and sequential pairings of TMS and ketamine for major depression and bipolar treatment resistance. The systematic data indicated:

Sustained Efficacy and Remission: Across long-term retrospective review footprints, patients receiving structured combination cycles (ranging from 10 to over 30 sessions) demonstrated significant reductions in standardized psychiatric clinical rating scales. Long-term follow-up verified that improvements in depression severity and psychosocial functioning were sustained for up to two years post-treatment.

Hyper-Refractory Case Efficacy: Peer-reviewed case reports confirm that when standalone TMS monotherapy and consecutive ketamine infusion monotherapies fail independently, a combined synchronized or sequential protocol can induce rapid clinical remission. For instance, a notable case of severe bipolar TRD complicated by generalized anxiety disorder achieved total, prolonged clinical remission (dropping a baseline Montgomery-Asberg Depression Rating Scale [MADRS] score from 38 down to 4) using a combined protocol of intermittent theta-burst stimulation (iTBS) and racemic ketamine.

Safety and Compliance Profile: Clinical reviews highlight that the adverse event profile of combined protocols is generally mild, non-severe, and transient. Reported side effects include temporary nausea, brief vertigo, mild dissociation during active drug delivery, local scalp discomfort, and the practical inconvenience of required fasting parameters. Crucially, real-world cohorts indicate a near-zero dropout or clinical attrition rate, suggesting that the protocol effectively overrides the tolerability barriers that normally disrupt standalone high-intensity neuromodulation treatments.

See also

• Transcranial magnetic stimulation
• Treatment-resistant depression
• Default mode network

References

• Arubuolawe, Oluwatosin O.; Folorunsho, Ibrahim L.; Busari, Adeniyi K.; Ibeneme, Chidalu; Diala, Amarachukwu B.; Afolabi, Victory I.; Harry, Nkechinyere M.; Anona, Kenechukwu; Obitulata-Ugwu, Vivien O.; Kuye, Olubukola A.; Anugwom, Gibson O. (2024). "Combination of Transcranial Magnetic Stimulation and Ketamine in Treatment-Resistant Depression: A Systematic Review". Cureus. 16 (7): e64712. doi:10.7759/cureus.64712. PMC 11327889 . PMID 39156335 .
• Ramakrishnan, Nithya; Murphy, Nicholas R. E.; Walker, Christopher P.; Cuellar Leal, Valeria A.; Soares, Jair C.; Cho, Raymond Y. J.; Selvaraj, Sudhakar (2019). "Neurophysiological Effect of Ketamine on Prefrontal Cortex in Treatment-Resistant Depression: A Combined Transcranial Magnetic Stimulation–Electroencephalography Study". Chronic Stress. 3. doi:10.1177/2470547019861417. PMC 7219868 . PMID 32440596 .
• Elkrief, Laurent; Payette, Olivier; Foucault, Jean-Nicolas; Longpré-Poirier, Christophe; Richard, Maxime; Desbeaumes Jodoin, Véronique; Lespérance, Paul; Miron, Jean-Philippe (2022). "Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report". Frontiers in Psychiatry. 13. doi:10.3389/fpsyt.2022.986378. PMC 9532540 . PMID 36213934 .
• Dębowska, Weronika; Więdłocha, Magdalena; Dębowska, Marta; Kownacka, Zuzanna; Marcinowicz, Piotr; Szulc, Agata (2023). "Transcranial magnetic stimulation and ketamine: Implications for combined treatment in depression". Frontiers in Neuroscience. 17. doi:10.3389/fnins.2023.1267647. PMC 10637948 . PMID 37954877 .
• Best, Steven R.D.; Pavel, Dan G.; Haustrup, Natalie (2019). "Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use". Heliyon. 5 (8). Bibcode:2019Heliy...502187B. doi:10.1016/j.heliyon.2019.e02187. PMC 6700321 . PMID 31440588.

This article "Synchronized drug-device neuroplasticity" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Synchronized drug-device neuroplasticity. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

---